SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 224 filers reported holding SAGE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $747,098 | -71.1% | 17,805 | -73.7% | 0.17% | -72.8% |
| Q4 2022 | $2,586,083 | -58.2% | 67,805 | -57.0% | 0.62% | -49.3% |
| Q3 2022 | $6,180,000 | -23.5% | 157,805 | -36.9% | 1.23% | -16.4% |
| Q2 2022 | $8,075,000 | -51.2% | 250,000 | -50.0% | 1.47% | -32.4% |
| Q1 2022 | $16,547,000 | +8518.2% | 499,907 | +11009.0% | 2.18% | +7403.4% |
| Q4 2021 | $192,000 | -99.3% | 4,500 | -99.1% | 0.03% | -98.7% |
| Q2 2021 | $28,647,000 | -14.1% | 504,300 | +13.2% | 2.32% | +106.2% |
| Q1 2021 | $33,341,000 | +160.6% | 445,451 | +201.3% | 1.12% | +99.1% |
| Q4 2020 | $12,792,000 | +7.1% | 147,851 | -24.4% | 0.56% | -34.8% |
| Q3 2020 | $11,946,000 | -33.3% | 195,451 | -54.6% | 0.86% | -39.3% |
| Q2 2020 | $17,898,000 | +84.7% | 430,451 | +27.6% | 1.42% | +95.7% |
| Q1 2020 | $9,688,000 | +0.9% | 337,351 | +153.6% | 0.73% | -53.2% |
| Q4 2019 | $9,601,000 | – | 133,000 | – | 1.56% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,966,688 | $120,204,000 | 10.81% |
| Integral Health Asset Management, LLC | 230,000 | $14,058,000 | 4.30% |
| Asymmetry Capital Management, L.P. | 102,462 | $6,262,000 | 4.02% |
| ACUTA CAPITAL PARTNERS, LLC | 225,000 | $13,752,000 | 3.74% |
| DAFNA Capital Management LLC | 158,306 | $9,676,000 | 3.14% |
| Bain Capital Life Sciences Investors, LLC | 499,100 | $30,505,000 | 2.84% |
| Boxer Capital, LLC | 1,094,000 | $66,865,000 | 2.31% |
| Palo Alto Investors LP | 590,200 | $36,073,000 | 1.98% |
| Logos Global Management LP | 250,000 | $15,280,000 | 1.96% |
| Bellevue Group AG | 1,579,504 | $96,539,000 | 1.33% |